Rapid HIV Treatment Initiation, Access and Engagement in Care

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

September 13, 2020

Study Completion Date

September 13, 2020

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Dolutegravir 50 MG

Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.

DRUG

Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet [DESCOVY]

Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy) 1 tablet by mouth daily. Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Johns Hopkins University

OTHER

NCT03512964 - Rapid HIV Treatment Initiation, Access and Engagement in Care | Biotech Hunter | Biotech Hunter